Report : Asia Pacific Malaria Treatment Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Treatment Type (Antimalarial Agents, and Diagnostic Test); Route of Administration (Oral, and Parenteral); End User (Hospitals, Specialty Clinics, and Others)
At 6.7% CAGR, the Asia Pacific Malaria Treatment Market is speculated to be worth US$ 347.39 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific malaria treatment market was valued at US$ 235.63 million in 2022 and is expected to reach US$ 347.39 million by 2028, registering a CAGR of 6.7% from 2022 to 2028. Increasing prevalence of malaria and vaccines and government and private sector’s initiatives to raise awareness about malaria are the critical factors attributed to the Asia Pacific malaria treatment market expansion.
According to the World Health Organization (WHO), Malaria is an acute febrile illness caused by plasmodium parasites, which spread through the bites of infected female Anopheles mosquitoes. Malaria is caused by 5 parasite species in humans, and 2 of these species—Plasmodium falciparum and P. vivax—pose the greatest threat. P. vivax has been a causal agent of 2% (4.5 million) of the total cases mostly from Asia. According to WMR 2021, ∼2% of the global burden of malaria is borne by Southeast Asian countries, and India contributed 83% of estimated malaria cases and 82% of malaria deaths in Southeast Asia in 2020. The rising prevalence of malaria in different countries across the region boosts the Asia Pacific malaria treatment market growth.
On the contrary, counterfeit antimalarial drugs and subsequent drug resistance hurdles the growth of Asia Pacific malaria treatment market.
Based on treatment, the Asia Pacific malaria treatment market is segmented into prescription medications, vaccines, diagnostic tests, and others. The diagnostic tests segment held 43.2% market share in 2022, amassing US$ 101.76 million. It is projected to garner US$ 147.53 million by 2028 to expand at 6.4% CAGR during 2022–2028. Further, prescription medications segment is further categorized into chloroquine phosphate, artemisinin-based combination therapies (ACTs), atovaquone-proguanil, quinine sulfate (qualaquin) with doxycycline, primaquine phosphate, and others.
Based on drug type, the Asia Pacific malaria treatment market is bifurcated into branded and generic. The generic segment held 53.5% market share in 2022, amassing US$ 126.06 million. It is projected to garner US$ 181.63 million by 2028 to expand at 6.3% CAGR during 2022–2028.
Based on route of administration, the Asia Pacific malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment held 70.5% market share in 2022, amassing US$ 166.24 million. It is projected to garner US$ 242.59 million by 2028 to expand at 6.5% CAGR during 2022–2028.
Based on distribution channel, the Asia Pacific malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held 47.4% market share in 2022, amassing US$ 111.64 million. It is projected to garner US$ 165.27 million by 2028 to expand at 6.8% CAGR during 2022–2028.
Based on end user, the Asia Pacific malaria treatment market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment held 44.2% market share in 2022, amassing US$ 104.10 million. It is projected to garner US$ 148.49 million by 2028 to expand at 6.1% CAGR during 2022–2028.
Based on country, the Asia Pacific malaria treatment market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 29.3% market share in 2022. It was assessed at US$ 68.92 million in 2022 and is likely to hit US$ 100.57 million by 2028, exhibiting a CAGR of 6.5% during the forecast period.
Key players dominating the Asia Pacific malaria treatment market are AdvaCare Pharma USA LLC, Cipla Ltd, GSK Plc, Lupin Ltd, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Viatris Inc, VLP Therapeutics LLC, and Zydus Healthcare Ltd among others.
- In Sep 2022, GSK plc announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK’s groundbreaking malaria vaccine. This is the first prequalification for a malaria vaccine and is an important step in rolling out the vaccine in countries with moderate to high P. falciparum malaria transmission.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com